Gtn new updates
Asking for Preferences
No
Could you clarify what "GTN" refers to? For example:
- Glyceryl Trinitrate (nitroglycerin) - the drug used in angina/heart conditions
- Gestational Trophoblastic Neoplasia - a type of pregnancy-related tumor
- GTN - a company, technology, or something else entirely
What are you looking for updates on?
Gestational trophoblast neoplasia new updates
Reading File
Searching PubMed
gestational trophoblastic neoplasia treatment
Searching the Web
gestational trophoblastic neoplasia GTN new updates 2025 2026
Reading Web Page
https://www.figo.org/news/figo-updates-gestational-trophobla…
Reading Article
PMID: 40359461
Reading Article
PMID: 40031424
Here is a summary of the most important recent updates in GTN as of mid-2026:
Gestational Trophoblastic Neoplasia (GTN) - Key Updates 2025-2026
1. FIGO 2026 Revised Staging & Scoring System (BIGGEST UPDATE)
Published in the International Journal of Gynecology & Obstetrics, this is the most significant change in GTN classification in years. Key changes:
New Ultra-High-Risk Category
- The 2020 system had only low-risk and high-risk groups
- 2026 now adds a third tier: ultra-high-risk (WHO score ≥13)
- Induction chemotherapy (low-dose etoposide + cisplatin, twice weekly for 2-3 weeks) before standard EMA/CO is now formally recommended for ultra-high-risk patients, with survival rates of 80-85%
- This change formalizes existing practice into official guidance
Previous Chemotherapy Removed from Risk Scoring
- Earlier, prior chemotherapy was a factor in risk scoring
- Removed because restaging is NOT recommended for recurrent GTN, making this factor clinically irrelevant for initial risk assessment
New Separate Staging for PSTT and ETT
- Previously, PSTT and ETT were staged using the same WHO scoring system as other GTN subtypes - this was always recognized as imperfect since these tumors behave very differently
- The 2026 system introduces anatomical staging specifically for PSTT/ETT
- For Stage I-III disease, the key prognostic factor is the interval from the antecedent pregnancy (not WHO score)
- Risk scoring is no longer used for PSTT/ETT at all
Expanded Explanatory Notes
- More detailed guidance on interpreting diagnostic criteria, imaging, and pathology to help clinicians apply the system consistently across different settings
2. First Global Consensus Guidelines (EOTTD-ESGO-GCIG-ISSTD, 2025)
A landmark collaboration - the first global consensus-based guidelines for GTD, published in Journal of Clinical Oncology (June 2025), involving 53 expert GTD clinicians from 31 countries across 4 major international organizations:
- Formulated 9 consensus-based definitions of GTD terms
- Defined minimum criteria for what constitutes a GTD center
- Produced 18 flow diagrams covering diagnosis, treatment, and follow-up for all forms of primary and recurrent GTD
- This matters because many different treatment protocols existed worldwide with no unified framework - this is the first attempt to harmonize global practice [PMID: 40359461]
3. Pembrolizumab for Chemoresistant/Relapsed GTN (Meta-Analysis, 2025)
A systematic review and meta-analysis (Barcellos et al., 2025) of pembrolizumab in GTN found:
- Complete sustained remission in 71.59% (95% CI 53.27-84.78%) of chemoresistant or relapsed GTN cases
- Efficacy was consistent regardless of: patient age (<40 vs ≥40), histopathology (including PSTT/ETT), time from diagnosis to starting immunotherapy, and whether pembrolizumab was combined with chemotherapy or used alone
- This positions pembrolizumab as a viable salvage option for multi-drug resistant GTN, including the difficult-to-treat PSTT/ETT subtypes [PMID: 40031424]
4. Fertility-Sparing Surgery in Low-Risk GTN (Cochrane Review, 2024)
A Cochrane systematic review (Boonyapipat et al., 2024) evaluated fertility-sparing surgical interventions for low-risk, non-metastatic GTN. Key finding: uterine curettage may help reduce subsequent chemotherapy cycles in selected patients, supporting individualized fertility preservation approaches [PMID: 39312299].
5. Fertility-Sparing Treatment in PSTT (Systematic Review, 2026)
A new systematic review (Fotiou et al., 2026) specifically addressed fertility preservation in PSTT, where hysterectomy has historically been the standard. Results suggest selected PSTT patients with favorable features (early-stage, short interval from antecedent pregnancy) may be managed without hysterectomy, though evidence remains limited [PMID: 40628611].
6. NCCN Guidelines Update (Version 2.2026, November 2025)
NCCN released Version 2.2026 of its GTN guidelines in November 2025, incorporating current evidence on ultra-high-risk management and immune checkpoint inhibitor use in refractory disease.
Summary Table of Key Changes
| Area | Previous | 2025-2026 Update |
|---|---|---|
| Risk groups | Low-risk / High-risk | + Ultra-high-risk (WHO ≥13) |
| PSTT/ETT staging | WHO scoring | Anatomical staging + antecedent pregnancy interval |
| Risk scoring factor | Included prior chemo | Removed prior chemo from score |
| Salvage therapy | EMA/EP, TP/TE | Pembrolizumab - 71.6% remission rate |
| Global guidelines | Fragmented by region | First unified global consensus (EOTTD-ESGO-GCIG-ISSTD) |
The biggest takeaway: the 2026 FIGO staging overhaul and the first-ever global consensus guidelines represent a major step toward standardized GTN management worldwide, while pembrolizumab data is solidifying immunotherapy's role in chemoresistant disease.
This is a shared conversation. Sign in to Orris to start your own chat.